MYO7A and Stargardt disease: A lentiviral strategy delivering a wild-type copy of ABCA4 for the treatment of Stargardt disease, as well as MYO7A for the treatment of Usher syndrome, type 1B, were studied in Phase 1/2 clinical trials, but these studies were discontinued by the sponsor (ABCA4, NCT01736592, NCT01367444; MYO7A, NCT01505062 Sanofi) [114] (Table 1).